Current and emerging pharmacological treatment options for dementia

Behavioural Neurology

Volumn 17, Issue 1, 2006, Pages 5-16

  Ringman, John M ^a,b   Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Dementia; Dementia with Lewy Bodies; Frontotemporal dementia; Memantine; Parkinson's disease; Review; Treatment; Vascular dementia

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID ANTIBODY; AMYLOID PROTEIN; ANTIBODY; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEMANTINE; MUSCARINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PLACEBO; RESVERATROL; RIVASTIGMINE; SELEGILINE; STATINE DERIVATIVE; TACRINE; THIOCTIC ACID; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

AGITATION; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANOREXIA; BEHAVIOR DISORDER; BRADYCARDIA; BRAIN ISCHEMIA; CLINICAL TRIAL; COGNITION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FRONTOTEMPORAL DEMENTIA; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LEWY BODY; LIVER TOXICITY; META ANALYSIS; MULTIINFARCT DEMENTIA; MUSCLE CRAMP; NAUSEA; NONHUMAN; PALLIATIVE THERAPY; PARALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; STOMACH ACID SECRETION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 33646704005     PISSN: 09534180     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/315386     Document Type: Review

References (74)

1. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas, L.J. Thal and A.s.D.C. Study, Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial, JAMA 289 (2003), 2819-2826.
2. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R.E. Mrak, I.R. Mackenzie, P.L. McGeer, M.K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyama, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk and T. Wyss-Coray, Inflammation in Alzheimer's disease, Neurobiol Aging 21 (2000), 383-421.
3. R. Anand, R. Hartman, H. Sohn, J. Danyluk and S.M. Graham, Impact of study design and patient population on outcomes from cholinesterase inhibitor trials, Am J Geriatr Psychiatry 11 (2003), 160-168.
4. W.W. Barker, C.A. Luis, A. Kashuba, M. Luis, D.G. Harwood, D. Loewenstein, C. Waters, P. Jimison, E. Shepherd, S. Sevush, N. Graff-Radford, D. Newland, M. Todd, B. Miller, M. Gold, K. Heilman, L. Doty, I. Goodman, B. Robinson, G. Pearl, D. Dickson and R. Duara, Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank, Alzheimer Dis Assoc Disord 16 (2002), 203-212.
5. D.Q. Beversdorf, J.L. Warner, R.A. Davis, U.K. Sharma, H.N. Nagaraja and D.W. Scharre, Donepezil in the treatment of dementia with lewy bodies, Am J Geriatr Psychiatry 12 (2004), 542-544.
6. T. Bird, D. Knopman, J. VanSwieten, S. Rosso, H. Feldman, H. Tanabe, N. Graff-Raford, D. Geschwind, P. Verpillat and M. Hutton, Epidemiology and genetics of frontotemporal dementia/Pick's disease, Ann Neurol 54(Suppl 5) (2003), S29-31.
7. B.F. Boeve, M.H. Silber, T.J. Ferman, E. Kokmen, G.E. Smith, R.J. Ivnik, J.E. Parisi, E.J. Olson and R.C. Petersen, REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease, Neurology 51 (1998), 363-370.
8. R.A. Cherny, C.S. Atwood, M.E. Xilinas, D.N. Gray, W.D. Jones, C.A. McLean, K.J. Barnham, I. Volitakis, F.W. Fraser, Y. Kim, X. Huang, L.E. Goldstein, R.D. Moir, J.T. Lim, K. Beyreuther, H. Zheng, R.E. Tanzi, C.L. Masters and A.I. Bush, Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice, Neuron 30 (2001), 665-676.
9. J. Corey-Bloom, R. Anand and J. Veach, A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inihbitor, in patients with mild to moderately severe Alzheimer's disease, International Journal of Geriatric Psychopharmacology 1 (1998), 55-65.
10. C. Courtney, D. Farrell, R. Gray, R. Hills, L. Lynch, E. Sellwood, S. Edwards, W. Hardyman, J. Raftery, P. Crome, C. Lendon, H. Shaw and P. Bentham, Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial, Lancet 363 (2004), 2105-2115.
11. J. Couzin, Clinical trials. Nail-biting time for trials of COX-2 drugs, Science 306 (2004), 1673-1675.
12. J.L. Cummings, The dementias of Parkinson's disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type, European Neurology 28 (1988), 15-23.
13. J.L. Cummings and G. Cole, Alzheimer disease, Jama 287 (2002), 2335-2338.
14. J.L. Cummings and D. Kaufer, Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited, Neurology 47 (1996), 876-883.
15. J.L. Cummings, M. Mega, K. Gray, K. M., S. Rosenberg-Thompson, D.A. Carusi and J. Gorbein, The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia, Neurology 44 (1994), 2308-2314.
16. R.S. Doody, D.S. Geldmacher, B. Gordon, C.A. Perdomo and R.D. Pratt, Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease, Arch Neurol 58 (2001), 427-433.
17. R.S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky and J.L. Cummings, Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology 56 (2001), 1154-1166.
18. M. Emre, D. Aarsland, A. Albanese, E.J. Byrne, G. Deuschl, P.P. De Deyn, F. Durif, J. Kulisevsky, T. van Laar, A. Lees, W. Poewe, A. Robillard, M.M. Rosa, E. Wolters, P. Quarg, S. Tekin and R. Lane, Rivastigmine for dementia associated with Parkinson's disease, N Engl J Med 351 (2004), 2509-2518.
19. T. Erkinjuntti, A. Kurz, S. Gauthier, R. Bullock, S. Lilienfeld and C.V. Damaraju, Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial, Lancet 359 (2002), 1283-1290.
20. M. Etminan, S. Gill and A. Samii, Effect of non-steroidal antiinflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies, BMJ 327 (2003), 128.
21. M. Farlow, R. Anand, J. Messina, Jr., R. Hartman and J. Veach, A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease, Eur Neurol 44 (2000), 236-241.
22. M. Farlow, S.I. Gracon, L.A. Hershey, K.W. Lewis, C.H. Sadowsky and J. Dolan-Ureno, A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group, JAMA 268 (1992), 2523-2529.
23. M. Farlow, S. Potkin, B. Koumaras, J. Veach and D. Mirski, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Arch Neurol 60 (2003), 843-848.
24. H. Feldman, S. Gauthier, J. Hecker, B. Vellas, P. Subbiah and E. Whalen, A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease, Neurology 57 (2001), 613-620.
25. T.E. Finucane, Another advertisement for donepezil, J Am Geriatr Soc 52 (2004), 843; author reply 845-846.
26. R.A. Floyd and K. Hensley, Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases, Neurobiol Aging 23 (2002), 795-807.
27. H. Geerts, NC-531 (Neurochem), Curr Opin Investig Drugs 5 (2004), 95-100.
28. D.S. Geldmacher, G. Provenzano, T. McRae, V. Mastey and J.R. Ieni, Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease, J Am Geriatr Soc 51 (2003), 937-944.
29. D.S. Gelinas, K. DaSilva, D. Fenili, P. St George-Hyslop and J. McLaurin, Immunotherapy for Alzheimer's disease, Proc Natl Acad Sci USA 101(Suppl 2) (2004), 14657-14662.
30. A.L. Harvey, The pharmacology of galanthamine and its analogues, Pharmacol Ther 68 (1995), 113-128.
31. L.E. Hebert, P.A. Scherr, L.A. Beckett, M.S. Albert, D.M. Pilgrim, M.J. Chown, H.H. Funkenstein and D.A. Evans, Age-specific incidence of Alzheimer's disease in a community population, Jama 273 (1995), 1354-1359.
32. R. Hebert, M.F. Dubois, C. Wolfson, L. Chambers and C. Cohen, Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging, J Gerontol A Biol Sci Med Sci 56 (2001), M693-699.
33. K. Hoglund, K.M. Thelen, S. Syversen, M. Sjogren, K. von Bergmann, A. Wallin, E. Vanmechelen, H. Vanderstichele, D. Lutjohann and K. Blennow, The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer's Disease, Dement Geriatr Cogn Disord 19 (2005), 256-265.
34. K. Jellinger, W. Danielczyk, P. Fischer and E. Gabriel, Clinicopathological analysis of dementia disorders in the elderly, J Neurol Sci 95 (1990), 239-258.
35. D.S. Knopman, S.T. DeKosky, J.L. Cummings, H. Chui, J. Corey-Bloom, N. Relkin, G.W. Small, B. Miller and J.C. Stevens, Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology 56 (2001), 1143-1153.
36. P.L. Le Bars, M.M. Katz, N. Berman, T.M. Itil, A.M. Freedman and A.F. Schatzberg, A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia, North American EGb Study Group, Jama 278 (1997), 1327-1332.
37. S.A. Lipton and P.A. Rosenberg, Excitatory amino acids as a final common pathway for neurologic disorders, N Engl J Med 330 (1994), 613-622.
38. A. Maelicke, M. Samochocki, R. Jostock, A. Fehrenbacher, J. Ludwig, E.X. Albuquerque and M. Zerlin, Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease, Biol Psychiatry 49 (2001), 279-288.
39. I. McKeith, T. Del Ser, P. Spano, M. Emre, K. Wesnes, R. Anand, A. Cicin-Sain, R. Ferrara and R. Spiegel, Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study, Lancet 356 (2000), 2031-2036.
40. I.G. McKeith, D. Galasko, K. Kosaka, E.K. Perry, D.W. Dickson, L.A. Hansen, D.P. Salmon, J. Lowe, S.S. Mirra, E.J. Byrne, G. Lennox, N.P. Quinn, J.A. Edwardson, P.G. Ince, C. Bergeron, A. Burns, B.L. Miller, S. Lovestone, D. Collerton, E.N. Jansen, C. Ballard, R.A. de Vos, G.K. Wilcock, K.A. Jellinger and R.H. Perry, Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop, Neurology 47 (1996), 1113-1124.
41. M.S. Mega, J.L. Cummings, T. Fiorello and J. Gornbein, The spectrum of behavioral changes in Alzheimer's disease, Neurology 46 (1996), 130-135.
42. M.F. Mendez, A.R. Mastri, J.H. Sung and W.H. Frey, 2nd, Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases, Alzheimer Dis Assoc Disord 6 (1992), 35-43.
43. E.R. Miller, 3rd, R. Pastor-Barriuso, D. Dalal, R.A. Riemersma, L.J. Appel and E. Guallar, Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality, Ann Intern Med 142 (2005), 37-46.
44. R.C. Mohs, R.S. Doody, J.C. Morris, J.R. Ieni, S.L. Rogers, C.A. Perdomo and R.D. Pratt, A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients, Neurology 57 (2001), 481-488.
45. P.J. Neumann, R.C. Hermann, K.M. Kuntz, S.S. Araki, S.B. Duff, J. Leon, P.A. Berenbaum, P.A. Goldman, L.W. Williams and M.C. Weinstein, Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease, Neurology 52 (1999), 1138-1145.
46. L. Pantoni, Treatment of vascular dementia: evidence from trials with non-cholinergic drugs, J Neurol Sci 226 (2004), 67-70.
47. E.K. Perry, M. Curtis, D.J. Dick, J.M. Candy, J.R. Atack, C.A. Bloxham, G. Blessed, A. Fairbairn, B.E. Tomlinson and R.H. Perry, Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease, J Neurol Neurosurg Psychiatry 48 (1985), 413-421.
48. E.K. Perry, V. Haroutunian, K.L. Davis, R. Levy, P. Lantos, S. Eagger, M. Honavar, A. Dean, M. Griffiths, I.G. McKeith et al., Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease, Neuroreport 5 (1994), 747-749.
49. E.K. Perry, R.H. Perry and B.E. Tomlinson, Dietary lecithin supplements in dementia of Alzheimer type, Lancet 2 (1977), 242-243.
50. R.C. Petersen, R.G. Thomas, M. Grundman, D. Bennett, R. Doody, S. Ferris, D. Galasko, S. Jin, J. Kaye, A. Levey, E. Pfeiffer, M. Sano, C.H. van Dyck and L.J. Thal, Alzheimer's Disease Cooperative Study Group, Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med 352 (2005), 2379-2388
51. L. Puglielli, R.E. Tanzi and D.M. Kovacs, Alzheimer's disease: the cholesterol connection, Nat Neurosci 6 (2003), 345-351.
52. M.A. Raskind, E.R. Peskind, T. Wessel and W. Yuan, Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group, Neurology 54 (2000), 2261-2268.
53. S.L. Read, J. Frazee, J. Shapira, C. Smith, J.L. Cummings and U. Tomiyasu, Intracerebroventricular bethanechol for Alzheimer's disease. Variable dose-related responses, Arch Neurol 47 (1990), 1025-1030.
54. B. Reisberg, R. Doody, A. Stoffler, F. Schmitt, S. Ferris and H.J. Mobius, Memantine in moderate-to-severe Alzheimer's disease, N Engl J Med 348 (2003), 1333-1341.
55. S.L. Rogers, R.S. Doody, R.C. Mohs and L.T. Friedhoff, Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group, Arch Intern Med 158 (1998), 1021-1031.
56. S.L. Rogers, M.R. Farlow, R.S. Doody, R. Mohs and L.T. Friedhoff, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group, Neurology 50 (1998), 136-145.
57. M. Rosler, R. Anand, A. Cicin-Sain, S. Gauthier, Y. Agid, P. Dal-Bianco, H.B. Stahelin, R. Hartman and M. Gharabawi, Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial, BMJ 318 (1999), 633-638.
58. M. Rosler, W. Retz, P. Retz-Junginger and H.J. Dennler, Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease, Behav Neurol 11 (1998), 211-216.
59. S.M. Rosso, L. Donker Kaat, T. Baks, M. Joosse, I. de Koning, Y. Pijnenburg, D. de Jong, D. Dooijes, W. Kamphorst, R. Ravid, M.F. Niermeijer, F. Verheij, H.P. Kremer, P. Scheltens, C.M. van Duijn, P. Heutink and J.C. van Swieten, Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study, Brain 126 (2003), 2016-2022.
60. M. Sano, C. Ernesto, R.G. Thomas, M.R. Klauber, K. Schafer, M. Grundman, P. Woodbury, J. Growdon, C.W. Cotman, E. Pfeiffer, L.S. Schneider and L.J. Thal, A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study, N Engl J Med 336 (1997), 1216-1222.
61. N.R. Selden, D.R. Gitelman, N. Salamon-Murayama, T.B. Parrish and M.M. Mesulam, Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain, Brain 121 (Pt 12) (1998), 2249-2257.
62. D.J. Selkoe, Alzheimer disease: mechanistic understanding predicts novel therapies, Ann Intern Med 140 (2004), 627-638.
63. E. Siemers, J.F. Quinn, J. Kaye, M. Farlow, A.P. Porsteinsson, P.N. Tariot, P. Zoulnouni, J.E. Galvin, D.M. Holtzman, D. Knopman, J. Satterwhite, R.A. Dean and P.C. May, Effect of LY450139, a functional gamma-secretase inhibitor, on plasma and cerebrospinal fluid concentrations of Abeta and cognitive functioning in patients with mild-to-moderate Alzheimer's disease, in: American Academy of Neurology, San Francisco, CA, 2004, p. A174, Abstract.
64. C.M. Spencer and S. Noble, Rivastigmine. A review of its use in Alzheimer's disease, Drugs Aging 13 (1998), 391-411.
65. J.R. Swartz, B.L. Miller, I.M. Lesser and A.L. Darby, Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors, J Clin Psychiatry 58 (1997), 212-216.
66. P.N. Tariot, J.L. Cummings, I.R. Katz, J. Mintzer, C.A. Perdomo, E.M. Schwam and E. Whalen, A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting, J Am Geriatr Soc 49 (2001), 1590-1599.
67. P.N. Tariot, M.R. Fallow, G.T. Grossberg, S.M. Graham, S. McDonald and I. Gergel, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, Jama 291 (2004), 317-324.
68. P.N. Tariot, P.R. Solomon, J.C. Morris, P. Kershaw, S. Lilienfeld and C. Ding, A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group, Neurology 54 (2000), 2269-2276.
69. N.H. Trinh, J. Hoblyn, S. Mohanty and K. Yaffe, Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis, Jama 289 (2003), 210-216.
70. H.V. Vinters, W.G. Ellis, C. Zarow, B.W. Zaias, W.J. Jagust, W.J. Mack and H.C. Chui, Neuropathologic substrates of ischemic vascular dementia, J Neuropathol Exp Neurol 59 (2000), 931-945.
71. P.J. Whitehouse, D.L. Price, R.G. Struble, A.W. Clark, J.T. Coyle and M.R. Delon, Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain, Science 215 (1982), 1237-1239.
72. D. Wilkinson, R. Doody, R. Helme, K. Taubman, J. Mintzer, A. Kertesz and R.D. Pratt, Donepezil in vascular dementia: a randomized, placebo-controlled study, Neurology 61 (2003), 479-486.
73. B. Winblad, K. Engedal, H. Soininen, F. Verhey, G. Waldemar, A. Wimo, A.L. Wetterholm, R. Zhang, A. Haglund and P. Subbiah, A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD, Neurology 57 (2001), 489-495.
74. B. Winblad and N. Poritis, Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine), Int J Geriatr Psychiatry 14 (1999), 135-146.